TY - JOUR
T1 - Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties
AU - Benedetti, Maria Cristina
AU - D'andrea, Tiziano
AU - Colantoni, Alessio
AU - Silachev, Denis
AU - de Turris, Valeria
AU - Boussadia, Zaira
AU - Babenko, Valentina A.
AU - Volovikov, Egor A.
AU - Belikova, Lilia
AU - Bogomazova, Alexandra N.
AU - Pepponi, Rita
AU - Whye, Dosh
AU - Buttermore, Elizabeth D.
AU - Tartaglia, Gian Gaetano
AU - Lagarkova, Maria A.
AU - Katanaev, Vladimir L.
AU - Musayev, Ilya
AU - Martinelli, Simone
AU - Fucile, Sergio
AU - Rosa, Alessandro
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/3/15
Y1 - 2024/3/15
N2 - Pathogenic variants in the GNAO1 gene, encoding the alpha subunit of an inhibitory heterotrimeric guanine nucleotide-binding protein (Go) highly expressed in the mammalian brain, have been linked to encephalopathy characterized by different combinations of neurological symptoms, including developmental delay, hypotonia, epilepsy and hyperkinetic movement disorder with life-threatening paroxysmal exacerbations. Currently, there are only symptomatic treatments, and little is known about the pathophysiology of GNAO1-related disorders. Here, we report the characterization of a new in vitro model system based on patient-derived induced pluripotent stem cells (hiPSCs) carrying the recurrent p.G203R amino acid substitution in G alpha o, and a CRISPR-Cas9-genetically corrected isogenic control line. RNA-Seq analysis highlighted aberrant cell fate commitment in neuronal progenitor cells carrying the p.G203R pathogenic
AB - Pathogenic variants in the GNAO1 gene, encoding the alpha subunit of an inhibitory heterotrimeric guanine nucleotide-binding protein (Go) highly expressed in the mammalian brain, have been linked to encephalopathy characterized by different combinations of neurological symptoms, including developmental delay, hypotonia, epilepsy and hyperkinetic movement disorder with life-threatening paroxysmal exacerbations. Currently, there are only symptomatic treatments, and little is known about the pathophysiology of GNAO1-related disorders. Here, we report the characterization of a new in vitro model system based on patient-derived induced pluripotent stem cells (hiPSCs) carrying the recurrent p.G203R amino acid substitution in G alpha o, and a CRISPR-Cas9-genetically corrected isogenic control line. RNA-Seq analysis highlighted aberrant cell fate commitment in neuronal progenitor cells carrying the p.G203R pathogenic
KW - Encephalopathy
KW - Gnao1
KW - Induced pluripotent stem cell
KW - Movement disorder
KW - Neural rosette
KW - Wnt
UR - http://www.scopus.com/inward/record.url?scp=85186464713&partnerID=8YFLogxK
U2 - 10.1016/j.heliyon.2024.e26656
DO - 10.1016/j.heliyon.2024.e26656
M3 - Article
AN - SCOPUS:85186464713
SN - 2405-8440
VL - 10
JO - Heliyon
JF - Heliyon
IS - 5
M1 - e26656
ER -